PARIS, April 18 (Reuters) – Sartorius Stedim Biotech reported on Thursday a turnover down 8.2% in the first quarter in a context particularly of weak demand in China.
The turnover of the French pharmaceutical equipment supplier stood at 666.9 million euros over the period compared to 726.1 million euros last year.
The group confirmed its forecasts for 2024, still counting on a “moderate” first half with an expected improvement during the year. However, it warns of a possible impact on its activity of increased geopolitical tensions and the economic slowdown.
(Edited by Mathias de Rozario, edited by Blandine Hénault)
Which stocks to buy?
Making the best investments requires detailed knowledge of the markets, their mechanisms, the economy and involves delving into the heart of the strategy of each listed company. The Investir editorial team does it for you and provides its subscribers with advice on more than 800 stocks. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers